The Fractal Analytics IPO is open for public subscription today, 9 February 2026. Prior to the IPO opening, the company has raised ₹1,248 crore from anchor investors on February 6, 2026.
Issue Type: The IPO is a book-build issue of ₹2,833.9 crores, consisting of a fresh issue of ₹1,023.5 crores and an Offer-for-Sale (OFS) of ₹1,810.4 crores.
Lot Size: 16 shares
Price Band: ₹857-₹900 per share
Minimum Investment: ₹14,400 (for retail investors)
IPO Closing Date: February 11, 2026
Allotment Date: The basis of allotment will be finalised by February 12, 2026.
Listing Date: The tentative listing date on BSE and NSE is February 16, 2026.
Book Running Lead Manager: Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Private Limited, Goldman Sachs (India) Securities Private Limited and Axis Capital Limited
Registrar: MUFG Intime India Pvt Ltd
[9-February-2026 10:36:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
0.00 |
|
Non-Institutional Investors |
0.02 |
|
Retail Individual Investors (RIIs) |
0.11 |
|
Employees |
0.04 |
|
Total |
0.03 |
The net proceeds from the fresh issue will be used to fund the expenses towards the following objectives:
Explore other Upcoming IPOs on BSE and NSE.
As per media reports, the Grey Market Premium (GMP) of Fractal Analytics is reported at ₹35 over the IPO price.
Fractal Analytics is a globally acknowledged enterprise AI and analytics company focused on enabling better decision-making within organisations through advanced data and AI capabilities.
Established in 2000, their offerings span the full AI transformation journey, from strategy and design to deployment and scaling. As of September 30, 2025, our portfolio is structured into two core segments: Fractal.ai, which includes AI-led services and platforms hosted primarily on Cogentiq, and Fractal Alpha, which houses our AI-driven businesses.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.